Lexicon Pharma (LXRX) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.24 -0.88%
EPS Growth %: -50.0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -50.0%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $50 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Ardent Health revises 2025 non-GAAP figures after SEC staff talks
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
